Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced topline results from its Phase 1 trial of ZN-c5 in ER+/HER2- advanced breast cancer, reporting a clinical benefit rate of 40%. A Phase 2 trial is set to begin in H1 2021. The company has also raised approximately $166 million from its recent stock offering. Financial results show a net loss of $34.7 million for Q3 2020, up from $12.6 million in Q3 2019, with R&D expenses significantly increasing to $24.7 million, attributed to advancing multiple clinical trials amid ongoing COVID-19 disruptions.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a Key Opinion Leader (KOL) virtual meeting on September 24, 2020, focused on its WEE1 inhibitor, ZN-c3, for treating advanced solid tumors. Presenters include Dr. Kwok-Kin Wong and Dr. Gordon Mills, who will discuss the ongoing clinical strategy and the potential of ZN-c3 in cancer treatment. ZN-c3 aims to induce DNA damage in cancer cells to promote cell death and prevent tumor growth. A Phase 1/2 trial is underway, with plans for a Phase 1b trial combining ZN-c3 with chemotherapy in advanced ovarian cancer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will speak at two virtual investor conferences on September 17, 2020. The events are the Morgan Stanley 18th Annual Global Healthcare Conference at 8:45 a.m. ET and the Cantor Fitzgerald Virtual Global Healthcare Conference at 10:00 a.m. ET. Both presentations will be webcast live on Zentalis' website. The company focuses on developing small molecule therapeutics targeting cancer pathways, with a promising pipeline including ZN-c5 for breast cancer and other inhibitors.
On August 13, 2020, Zentalis Pharmaceuticals (ZNTL) announced key financial results for Q2 2020, highlighted by a successful IPO raising ~$190 million and a follow-on offering generating ~$144.4 million. The company also completed a $20 million Series A financing for its joint venture, Zentera Therapeutics. Strategic collaborations with Eli Lilly and Tavros Therapeutics were established to enhance their oncology pipeline. Despite a net loss of $27.3 million, Zentalis maintains a strong cash position of $233.2 million, which is expected to fund operations into 2023.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced a public offering of 4,125,000 shares of common stock at $35.00 per share, aiming for total gross proceeds of approximately $144.4 million. The offering is set to close on August 3, 2020, subject to customary conditions. Additionally, underwriters have a 30-day option to purchase up to 618,750 extra shares.
The effective registration statement was filed with the U.S. SEC on July 29, 2020. Zentalis focuses on developing small molecule therapeutics targeting cancer.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced a public offering of 3,750,000 shares of its common stock, with an additional 562,500 shares available for underwriters. The offering, managed by Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities, aims to provide funding for the company's oncology product development. While the registration statement has been filed with the SEC, it is not yet effective. Proceeds from the sale will potentially support their ongoing research and development in cancer therapeutics.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced a clinical collaboration with Eli Lilly to evaluate ZN-c5, a selective estrogen receptor degrader, in combination with Lilly's Verzenio for treating ER+/HER2- advanced breast cancer. This study aims to assess the potential of ZN-c5 alongside a CDK4 and 6 inhibitor, building upon existing therapies. Zentalis will conduct the trial while retaining ownership of ZN-c5, with Lilly providing Verzenio doses. ZN-c5 is currently in a Phase 1/2 trial as a monotherapy and with palbociclib, another collaboration with Pfizer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Kimberly Blackwell to its Board of Directors. A seasoned breast cancer researcher, Dr. Blackwell brings over 20 years of experience in the biopharmaceutical sector. Her previous roles include Chief Medical Officer at Tempus and Vice President of Early Phase Oncology at Eli Lilly. Dr. Blackwell's expertise in oncology will be crucial for advancing Zentalis's oncology pipeline. The company is focused on developing small molecule therapeutics targeting cancer pathways, including promising candidates like ZN-c5 and ZN-c3.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the presentation of preclinical data on ZN-c5 at the AACR Virtual Annual Meeting II from June 22-24, 2020. ZN-c5, an oral selective estrogen receptor degrader, showed anti-tumor activity in breast cancer models and favorable oral bioavailability across species. Currently under evaluation in a Phase 1/2 trial for ER+/HER2- advanced breast cancer, ZN-c5 may pave the way for improved treatment options in oncology.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Anthony Sun, MD, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 p.m. ET. A live webcast will be available on the company’s website, with an archived version accessible afterwards.
Zentalis focuses on developing novel small molecule therapeutics targeting cancer pathways, including its lead program, ZN-c5, an oral selective estrogen receptor degrader for breast cancer. For more information, visit www.zentalis.com.